Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in the UK / NCT07761299
Recruiting Observational

Versius Robotic Surgery in the NHS: A Multi-Specialty Retrospective Study

NCT07761299 · tracked via the Priya Life Science UK tracker
Sponsor
CMR Surgical Ltd
Phase
Observational
Started
2026-09-22
Last updated
2026-10-16

Condition(s) studied

Robotic-assisted Soft-tissue Surgery

Study summary

To generate robust, real-world comparative evidence on the short and long-term clinical outcomes following surgical intervention with Versius Robot-Assisted Surgery versus surgical standard of care across predefined soft-tissue index procedures in routine NHS practice.

Eligibility

Sex
ALL
Min age
—
Max age
—
Healthy volunteers
No
Inclusion Criteria: 1. Patients undergoing one of the index procedures with Versius, laparoscopically or with open surgery. 2. Patients who provide written consent (16 years or older) or for whom an appropriate legal representative who provides written informed consent (\<16 years old). Exclusion Criteria: 1. Patients participating in an interventional clinical study that might impact the defined endpoints. 2. Patients undergoing concomitant surgery. 3. Patients or appropriate legal representatives unwilling to provide written consent. 4. Patients with BMI at or above 40 kg/m2.

Primary outcome measure(s)

  • Procedure related complication rates — Within 30 days and 12 months after surgery
    Rate of total procedure related complications within 30 days and up to 12 months following surgery

Trial sites (5)

FacilityCityRegionStatus
St Thomas' Hospital London United Kingdom Not Yet Recruiting
Manchester University NHS Foundation Trust Manchester United Kingdom Not Yet Recruiting
University Hospital Southampton NHS Foundation Trust Southampton United Kingdom Not Yet Recruiting
Great Western Hospitals NHS Foundation Trust Swindon United Kingdom Not Yet Recruiting
Watford General Hospital Watford United Kingdom Recruiting

More CMR Surgical Ltd trials in the UK

Versius Paediatrics Study Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07761299 on ClinicalTrials.gov ↗ ← All trials in the UK